Significo Closes Series B Led by JSTAR Capital Investments' Horizon Fund II, Reaches $100M Valuation to Drive Digital Health Consolidation

AUSTIN, Texas, Oct. 1, 2025 /PRNewswire/ -- Significo, a leader in health AI and digital therapeutics, today announced the close of its Series B financing round led by JSTAR Capital Investments' Horizon Fund II, a premier growth investor in healthcare innovation. The raise brings Significo's valuation to $100 million and positions the company to accelerate its strategy of acquiring and integrating synergistic digital health companies.

With this financing, Significo will expand its portfolio, strengthen its market presence, and act as a consolidating force in an increasingly fragmented industry. The company is actively evaluating acquisitions that complement its existing products, including Balm, its digital therapeutic and condition management platform, and Recco, its personalized health recommendation engine.

"Digital health is at an inflection point," said Rick McCartney, CEO of Significo. "Patients, providers, and payors are looking for scalable, clinically validated solutions that deliver real outcomes. With JSTAR Capital Investments' backing, Significo is not only poised to scale our own platforms but also to bring together best-in-class digital health innovations under one roof. Our goal is to simplify technology adoption for healthcare providers to drive meaningful health outcomes at the population scale."

The Series B financing follows a period of strong commercial traction for Significo, including partnerships with leading insurers, health systems, and distribution networks. By consolidating proven digital therapeutics into a unified, comprehensive platform, Significo reduces fragmentation, improves patient engagement, and proves out a sustainable model for digital therapeutic reimbursement and adoption.

"We are excited to lead this financing round and support Significo in its mission to transform the digital health landscape," said Jared Leger, Managing Director at JSTAR Capital Investments.  "The team has a proven track record of execution, and their vision for consolidation and clinical impact is exactly what the industry needs" adds Evan Pritchard, Managing Director of JSTAR Capital Investments.

This Series B will fuel growth initiatives across product development, global expansion, and strategic acquisitions, furthering Significo's mission to make digital therapeutics accessible, effective, and integrated into everyday healthcare delivery.

About Significo
Significo is a global leader in health AI and digital therapeutics, building solutions that empower patients, providers, and payors with clinically validated interventions and personalized care. Its flagship platforms include Balm, a digital therapeutic delivery and reimbursement solution, and Recco, a personalized health recommendation engine. Significo partners with health systems, insurers, and employers worldwide to deliver scalable, effective, and engaging digital health experiences.
For more information, visit www.significo.com

About JSTAR Capital Investments
JSTAR Capital Investments is a growth-focused investment firm with a proven track record of supporting transformative companies in the healthcare, technology, and life sciences sectors. Through its Horizon Fund II, JSTAR provides capital and strategic support to entrepreneurs building the next generation of industry leaders.
For more information, visit jstarinvestments.com

Contact:
Christian Koha, Chief Operating Officer
E-mail: [email protected]

SOURCE Significo